AU2014233428B2 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases Download PDF

Info

Publication number
AU2014233428B2
AU2014233428B2 AU2014233428A AU2014233428A AU2014233428B2 AU 2014233428 B2 AU2014233428 B2 AU 2014233428B2 AU 2014233428 A AU2014233428 A AU 2014233428A AU 2014233428 A AU2014233428 A AU 2014233428A AU 2014233428 B2 AU2014233428 B2 AU 2014233428B2
Authority
AU
Australia
Prior art keywords
polynucleotide
alopecia
pro
apoptotic
cpg dinucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014233428A
Other languages
English (en)
Other versions
AU2014233428A1 (en
Inventor
Alan P. Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loma Linda University filed Critical Loma Linda University
Publication of AU2014233428A1 publication Critical patent/AU2014233428A1/en
Priority to AU2019219835A priority Critical patent/AU2019219835B2/en
Application granted granted Critical
Publication of AU2014233428B2 publication Critical patent/AU2014233428B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
AU2014233428A 2013-03-15 2014-03-14 Treatment of autoimmune diseases Active AU2014233428B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019219835A AU2019219835B2 (en) 2013-03-15 2019-08-23 Treatment of autoimmune diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800354P 2013-03-15 2013-03-15
US61/800,354 2013-03-15
PCT/US2014/029685 WO2014145042A1 (en) 2013-03-15 2014-03-14 Treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019219835A Division AU2019219835B2 (en) 2013-03-15 2019-08-23 Treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
AU2014233428A1 AU2014233428A1 (en) 2015-09-17
AU2014233428B2 true AU2014233428B2 (en) 2019-09-19

Family

ID=51537869

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014233428A Active AU2014233428B2 (en) 2013-03-15 2014-03-14 Treatment of autoimmune diseases
AU2019219835A Active AU2019219835B2 (en) 2013-03-15 2019-08-23 Treatment of autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019219835A Active AU2019219835B2 (en) 2013-03-15 2019-08-23 Treatment of autoimmune diseases

Country Status (8)

Country Link
EP (1) EP2968606B1 (enExample)
JP (3) JP6499155B2 (enExample)
CN (2) CN105451777A (enExample)
AU (2) AU2014233428B2 (enExample)
CA (1) CA2902565C (enExample)
DK (1) DK2968606T3 (enExample)
ES (1) ES2825078T3 (enExample)
WO (1) WO2014145042A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2758074T3 (da) 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗
WO2016135732A1 (en) * 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058393A1 (en) * 2005-05-11 2009-05-13 Loma Linda University Compositions and methods for preventing and treating immune-mediated inflammatory disorders
WO2013044177A2 (en) * 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US5549127A (en) 1995-05-03 1996-08-27 Chang; Wen-Hsiung Spring fixing structure for a hairgrip
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6233483B1 (en) 1997-05-14 2001-05-15 Pacesetter, Inc. System and method for generating a high efficiency biphasic defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD).
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
AU2868200A (en) 1999-02-08 2000-08-25 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
EP1890606A1 (en) * 2005-04-25 2008-02-27 Koninklijke Philips Electronics N.V. Method and apparatus for continuous imaging by ultrasound transducer system
US20090191218A1 (en) * 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
WO2009114735A1 (en) * 2008-03-12 2009-09-17 Loma Linda University Dna vaccines and methods for the prevention of transplantation rejection
EP2542698B1 (en) 2010-03-03 2015-04-22 Zymo Research Corporation Detection of dna methylation
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058393A1 (en) * 2005-05-11 2009-05-13 Loma Linda University Compositions and methods for preventing and treating immune-mediated inflammatory disorders
WO2013044177A2 (en) * 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof

Also Published As

Publication number Publication date
AU2014233428A1 (en) 2015-09-17
JP2021091742A (ja) 2021-06-17
DK2968606T3 (da) 2020-10-26
EP2968606A4 (en) 2016-10-12
JP6499155B2 (ja) 2019-04-10
CA2902565A1 (en) 2014-09-18
EP2968606A1 (en) 2016-01-20
WO2014145042A1 (en) 2014-09-18
JP2016516725A (ja) 2016-06-09
CN110237270A (zh) 2019-09-17
AU2019219835B2 (en) 2021-10-07
EP2968606B1 (en) 2020-10-07
HK1220127A1 (en) 2017-04-28
ES2825078T3 (es) 2021-05-14
JP2019077715A (ja) 2019-05-23
AU2019219835A1 (en) 2019-09-12
CA2902565C (en) 2022-11-29
CN105451777A (zh) 2016-03-30

Similar Documents

Publication Publication Date Title
AU2019219835B2 (en) Treatment of autoimmune diseases
CN1759122B (zh) 包含mda-7的组合物和方法
UA109891C2 (uk) Композиція пухлиноасоційованих пептидів для лікування ракових захворювань
US20040009939A1 (en) Methods of enhancing immune induction involving MDA-7
US20160375091A1 (en) Composition for Treating Prostate Cancer
CN104271147A (zh) 细胞穿膜肽
US20150202248A1 (en) E2f as a target of hormone refractory prostate cancer
CA2570017A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
JP6169607B2 (ja) 抗腫瘍アジュバント療法
CN106222155B (zh) 一种多肽及其在制备结肠炎及结肠炎相关结直肠癌药物中的应用
US20240043866A1 (en) Treatment of autoimmune diseases
CN115490765A (zh) Gpnmb的表位肽及所述表位肽与热休克蛋白的复合物
HK1220127B (en) Treatment of autoimmune diseases
WO2015092756A1 (en) Recombinant fusion protein prostat and uses thereof
HK40013739A (en) Treatment of autoimmune diseases
CA2846865A1 (en) Use of hdl-related molecules to treat and prevent proinflammatory conditions
US20080293652A1 (en) Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
CN115490763A (zh) Lum的表位肽及所述表位肽与热休克蛋白的复合物
CN115490768A (zh) Col1a1的表位肽及所述表位肽与热休克蛋白的复合物
JPWO1997046676A1 (ja) 腫瘍抗原タンパク質、その遺伝子および腫瘍抗原ペプチド
HK1180218B (en) Methods and compositions involving mda-7

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)